Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion

Ophthalmic Research

Volumn 45, Issue 1, 2010, Pages 31-35

  Chuang, Lan Hsin ^a   Wu, Wei Chi ^a,b   Yeung, Ling ^a,b   Wang, Nan Kai ^a,b   Hwang, Yih Shiou ^a,b   Chen, Kuan Jen ^a,b   Kuo, Jane Zea Chin ^a   Lai, Chi Chun ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Bevacizumab; Branch retinal vein occlusion; Hypertension

Indexed keywords

BEVACIZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARGON LASER; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA EDEMA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; DISEASE MODELS, ANIMAL; HALF-LIFE; INTRAVITREAL INJECTIONS; RATS; RATS, SPRAGUE-DAWLEY; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77955531525     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315617     Document Type: Article

References (31)

1. Johnston RL, Brucker AJ, Steinmann W, Hoffman ME, Holmes JH: Risk factors of branch retinal vein occlusion. Arch Ophthalmol 1985; 103: 1831-1832.
2. Appiah AP, Trempe CL: Differences in contributory factors among hemicentral, central, and branch retinal vein occlusions. Ophthalmology 1989; 96: 364-366.
3. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Jian K, Sakamoto I, Nakano K, Yamashita H, Minamoto A, Mishima HK: Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005; 140: 256-261.
4. The Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98: 271-282.
5. Cakir M, Dogan M, Bayraktar Z, Bayraktar S, Acar N, Altan T, Kapran Z, Yilmaz OF: Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina 2008; 28: 465-472.
6. Cekic O, Chang S, Tseng JJ, Barile GR, Del Priore LV, Weissman H, Schiff WM, Ober MD: Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005; 25: 851-855. (Pubitemid 41456575)
7. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U: Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008; 92: 518-522.
8. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU: Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007; 27: 141-149.
9. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL: Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007; 27: 419-425.
10. Lynch SS, Cheng CM: Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007; 41: 614-625.
11. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A: Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005.
12. Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, Sawa M, Tsujikawa M, Kusaka S, Tano Y: Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008; 86: 372-376.
13. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-859.
14. Kamba T, McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96: 1788-1795.
15. Pande A, Lombardo J, Spangenthal E, Javle M: Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res 2007; 27: 3465-3470.
16. Lai CC, Wu WC, Chuang LH, Yeung L, Wei W, Yang KJ: Quantitative grading of preretinal neovascularization in adult rats. Acta Ophthalmol Scand 2005; 83: 590-594.
17. Ham DI, Chang K, Chung H: Preretinal neovascularization induced by experimental retinal vein occlusion in albino rats. Kor J Ophthalmol 1997; 11: 60-64.
18. Zhang Y, Fortune B, Atchaneeyasakul LO, McFarland T, Mose K, Wallace P, Main J, Wilson D, Appukuttan B, Stout JT: Natural history and histology in a rat model of laserinduced photothrombotic retinal vein occlusion. Cur Eye Res 2008; 33: 365-376.
19. Mitchell P, Smith W, Chang A: Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study. Arch Ophthalmol 1996; 114: 1243-1247. (Pubitemid 26338856)
20. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Hirayama T, Tamura H, Yamashita H, Minamoto A, Mishima HK: Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2008; 22: 42-48.
21. Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ, Evans T, Costa RA, Cardillo J, Pan-American Collaborative Retina Study Group: Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan- American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008; 28: 212-219.
22. O'Mahoney PR, Wong DT, Ray JG: Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008; 126: 692-699.
23. Daher IN, Yeh ET: Vascular complications of selected cancer therapies. Nat Clin Pract Card 2008; 5: 797-805.
24. Lee K, Yang H, Lim H, Lew HM: A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. Retina 2009; 29: 1409-1417.
25. Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, Sawa M, Tsujikawa M, Kusaka S, Tano Y: Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008; 86: 372-376.
26. Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H: The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye 2009; 23: 1714-1718.
27. Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, Blumenkranz MS: Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 2008; 28: 1151-1158.
28. Arias L, Caminal JM, Casas L, Masuet C, Badia MB, Rubio M, Pujol O, Arruga J: A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 2008; 92: 1636-1641.
29. Dib E, Maia M, Longo-Maugeri IM, Martins MC, Mussalem JS, Squaiella CC, Penha FM, Magalhaes O Jr, Rodrigues EB, Farah ME: Subretinal bevacizumab detection after intravitreous injection in rabbits. Invest Ophthalmol Vis Sci 2008; 49: 1097-1100.
30. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr: Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 2006; 26: 882-888.
31. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U: Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-2823.